Christopher Thomas Giordano - 09 Jan 2026 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role: CEO, Director
Signature: /s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol: TENX
Transactions as of: 09 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 13 Jan 2026, 21:37:38 UTC
Previous filing: 20 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Giordano Christopher Thomas	CEO, Director	101 GLEN LENNOX DRIVE SUITE 300, CHAPEL HILL	/s/ S. Halle Vakani, as Attorney-in-Fact	13 Jan 2026	0001871714

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TENX	Common Stock						2,605	09 Jan 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TENX	Stock Option (right to buy)	Award	$0	+450,000		$0.000000	450,000	09 Jan 2026	Common Stock	450,000	$13.30	Direct	F1
holding	TENX	Stock Option (right to buy)						157	09 Jan 2026	Common Stock	157	$3152.00	Direct	F2
holding	TENX	Stock Option (right to buy)						125	09 Jan 2026	Common Stock	125	$992.00	Direct	F3
holding	TENX	Stock Option (right to buy)						437	09 Jan 2026	Common Stock	437	$3.55	Direct	F4
holding	TENX	Stock Option (right to buy)						1,250,000	09 Jan 2026	Common Stock	1,250,000	$5.94	Direct
holding	TENX	Stock Option (right to buy)						1,400,000	09 Jan 2026	Common Stock	1,400,000	$5.89	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
F2	The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
F3	The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F4	The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
F5	The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.